Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.57M$17.57Mderived+126.6% vs Q4 2022 Net Income-$1.49M-$1.49MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,047,000N/M Operating Cash Flowderived-$6,761,000N/M Free Cash Flowderived-$7,202,000N/M Margins · derivedOperating margin-23.0%+352.0 pt vs Q4 2022
Net margin-8.5%+348.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 27, 2024 · 58 d after period end